Advances in treating psoriasis
Open Access
- 2 January 2014
- journal article
- review article
- Published by H1 Connect in F1000Prime Reports
- Vol. 6 (4), 4
- https://doi.org/10.12703/p6-4
Abstract
Psoriasis is a T helper (Th)17/Th1-mediated autoimmune disease affecting the skin and joints. So far, distinct traditional oral compounds and modern biologics have been approved in most countries for the treatment of patients with moderate to severe psoriasis or psoriatic arthritis. Yet, the anti-psoriatic therapeutic spectrum is to be extended by a number of novel targeted therapies including biologics and modern oral compounds. The next set of anti-psoriatic biologics targets mainly Th17-associated cytokines such as IL-17 or IL-23. In contrast, modern oral anti-psoriatics, such as dimethyl fumarate (DMF), apremilast or Janus kinase (JAK) inhibitors interfere with intracellular proteins and affect signaling pathways. Here we summarize the current systemic therapies for psoriasis and their immunological mechanism. The recent advances in psoriasis therapy will help treat our patients efficiently and complete our understanding of disease pathogenesis.Keywords
This publication has 64 references indexed in Scilit:
- Global Epidemiology of Psoriasis: A Systematic Review of Incidence and PrevalenceJournal of Investigative Dermatology, 2013
- T helper 17 cell heterogeneity and pathogenicity in autoimmune diseaseTrends in Immunology, 2011
- A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1Nature Genetics, 2010
- IL-17 as a future therapeutic target for rheumatoid arthritisNature Reviews Rheumatology, 2009
- The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17–producing effector T helper cells in vivoNature Immunology, 2009
- Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathwaysNature Genetics, 2009
- Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis VulgarisThe Journal of Experimental Medicine, 2004
- Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune diseaseNature Medicine, 2002
- Expression of Interleukin-12 is Increased in Psoriatic SkinJournal of Investigative Dermatology, 1998
- Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines.JCI Insight, 1994